Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders

Jiewei Liu1, Yuqi Cheng2, Ming Li3, Zhijun Zhang4, Tao Li3 and Xiong-Jian Luo3,4,5

© The Author(s), under exclusive licence to American College of Neuropsychopharmacology 2022

Psychiatric disorders impose tremendous economic burden on society and are leading causes of disability worldwide. However, only limited drugs are available for psychiatric disorders and the efficacy of most currently used drugs is poor for many patients. To identify novel therapeutic targets for psychiatric disorders, we performed genome-wide Mendelian randomization analyses by integrating brain-derived molecular quantitative trait loci (mRNA expression and protein abundance quantitative trait loci) of 1263 actionable proteins (targeted by approved drugs or drugs in clinical phase of development) and genetic findings from large-scale genome-wide association studies (GWASs). Using transcriptome data, we identified 25 potential drug targets for psychiatric disorders, including 12 genes for schizophrenia, 7 for bipolar disorder, 7 for depression, and 1 (TIE4) for attention deficit and hyperactivity. We also identified 10 actionable drug targets by using brain proteome data, including 4 (HLA-DRB1, CAMKK2, P2RX7, and MAPK3) for schizophrenia, 1 (PRKCB) for bipolar disorder, 6 (PSMB4, IMPDH2, SERPINC1, GRIA1, P2RX7 and TAOK3) for depression. Of note, MAPK3 and HLA-DRB1 were supported by both transcriptome and proteome-wide MR analyses, suggesting that these two proteins are promising therapeutic targets for schizophrenia. Our study shows the power of integrating large-scale GWAS findings and transcriptomic and proteomic data in identifying actionable drug targets. Besides, our findings prioritize actionable novel drug targets for development of new therapeutics and provide critical drug-repurposing opportunities for psychiatric disorders.

Neuropsychopharmacology (2023) 48:270–280; https://doi.org/10.1038/s41386-022-01456-5

INTRODUCTION

Psychiatric disorders (including schizophrenia, bipolar disorder (BP), depression and attention deficit and hyperactivity (ADHD)) impose enormous economic burden on society and are a major global public health threat [1, 2]. Due to the high prevalence, substantial mortality and morbidity, psychiatric disorders contributed about 14% of global burden of disease [1, 2]. Mental disorders affect about 18% population of the worldwide [3] and the global costs of mental disorders were estimated about 2.5 trillion US dollars in 2010 [4]. The COVID-19 pandemic further exacerbates the threat of psychiatric disorders [5]. There is a pressing need for efficient intervention and treatment of mental disorders.

So far, treatment of psychiatric disorders remains a major challenge. First, only limited drugs are available for psychiatric disorders [6–12]. Second, most of the approved drugs exert their therapeutic effects by targeting a small number of specific molecular targets. For example, almost all antipsychotics exert their therapeutic effects by antagonizing type 2 dopaminergic receptor (DRD2) [13–15], and most antidepressants targeting monoaminergic systems (including dopaminergic, noradrenergic and serotonergic systems) [16–18]. Third, in addition to beneficial therapeutic effects, antipsychotics and antidepressants also bring considerable side effects [19–27], including hyperlipidemia, myocardiitis, weight gain, sexual side effects, type II diabetes mellitus, etc. Fourth, many drugs take effect slowly (about several weeks). Finally, many patients do not respond to pharmacological treatment (i.e., treatment resistant) [28–34]. These challenges account for a large proportion of the enormous costs of psychiatric disorders.

Despite the fact that psychiatric disorders impose tremendous economic burden on society and are a major global public health threat, drugs discovery for psychiatric disorders gained little progress for decades [35–38]. Therapeutic stasis is mainly attributable to the unknown pathophysiology of psychiatric disorders. The rapid progress of genome-wide association studies (GWASs) provides an unprecedented opportunity for development of novel drugs for many complex diseases [39]. In the past two decades, GWASs have identified numerous risk variants and genes for many human complex diseases and traits, including psychiatric disorders such as schizophrenia [40–43], depression [44, 45], BP [46] and ADHD [47]. GWASs have also revealed important biological insights into psychiatric disorders [40], which will facilitate to the identification of new drugs targets and
development of new treatments. Nelson et al. showed that selecting genetically supported target genes (as therapeutic targets) could greatly increase the success rate of drug development [48], indicating the pivotal role of human genetic studies in drug discovery [49]. In fact, several new drugs have been successfully developed based on human genetic studies, including PCSK9 [50] and CCR5 [51].

Considering the huge time and economic costs of development of new drugs, integrating GWAS findings and approved drugs provides a unique opportunity for quick discovery of novel targets (drug repurposing or repositioning). Most of risk variants for complex diseases are though to exert their biological effects by affecting gene expression [52], thus, integration of GWAS and complex diseases are though to exert their biological effects by affecting gene expression [52], thus, integration of GWAS and complex diseases are though to exert their biological effects by affecting gene expression [52], thus, integration of GWAS and complex diseases are though to exert their biological effects by affecting gene expression [52], thus, integration of GWAS and complex diseases are though to exert their biological effects by affecting gene expression [52], thus, integration of GWAS and complex diseases are though to exert their biological effects by affecting gene expression [52], thus, integration of GWAS and complex diseases are though to exert their biological effects by affecting gene expression [52], thus, integration of GWAS and complex diseases are though to exert their biological effects by affecting gene expression [52], thus, integration of GWAS and complex diseases are though to exert their biological effects by affecting gene expression. As many drugs exert their therapeutic effects by down-regulating or up-regulating targeting proteins, associations between the disease-associated risk genetic variants (derived from GWAS) and gene or protein expression provide a useful opportunity for drug repurposing. Risk genetic variants that mimic the therapeutic effects of approved drugs can inform drug development. Focusing on actionable proteins (targeted by approved drugs or drugs in clinical phase of development) provide a rapid and efficient approach for drug repurposing as the safety and dose of the approved drugs have been well-established.

To identify new drug targets and to seek potential drug repurposing opportunities for psychiatric disorders, we performed MR by integrating GWAS findings from large-scale human genetic studies and brain-derived molecular quantitative trait loci (mRNA expression and protein abundance quantitative trait loci) of 1,263 actionable proteins (targeted by approved drugs or drugs in clinical phase of development). We identified promising actionable novel drug targets for psychiatric disorders, including TIE1, AKT3, HLA-DRB1, P2RX7, PSMA4, MAPK3, CACNA1C, PRKCB, PSMB4, IMPDH2, GRIA1 and TAOK3.

MATERIALS AND METHODS

Actionable drug targets

We used 1263 actionable drug targets (approved drugs or drugs in clinical phase of development) curated by Gaziano et al. [60] as potential candidates in this study. To identify drug repurposing opportunity for COVID-19, Gaziano et al. [60] curated 1263 actionable proteins targeted by approved drugs (or drugs in clinical phase of development) using the ChemBL database [60, 61]. Among these 1263 proteins, 531 proteins are therapeutic targets of approved drugs, 381 proteins are under clinical trial evaluation and 351 proteins are potential drug targets of the approved drugs. More detailed information about these actionable drug targets have been described in study by Gaziano et al. [60].

QTL datasets used for genetic instrumental variables selection

We used 3 QTL datasets to derive genetic instrumental variables. The first dataset is the expression quantitative trait loci (eQTL) data from The Genotype-Tissue Expression (GTEX) [62], the second dataset is the PsychENCODE eQTL [63], and the last dataset is ROSMAP protein abundance quantitative trait loci (pQTL) [64].

GTEX eQTL. We downloaded GTEX eQTL data [62] using the MRInstruments R package (https://github.com/mrcieu/minstruments). As we focused on psychiatric disorders, we firstly extracted brain eQTL from all the GTEX results and obtained 35,673 conditionally independent cis SNPs that were associated with gene expression. We further investigated if genes whose expression were associated with these SNPs were included in the 1263 actionable drug targets. Genetic variants associated with expression of actionable drug targets (eQTL P < 1 x 10^{-6}) were selected for subsequent analysis, as described in recent studies [65, 66]. As MRInstruments R package uses top eQTL hit of each gene across 44 tissues of GTEX (i.e. one gene corresponds one instrument, and the selected instrument shows the most significant association with the gene in the GTEX eQTL summary statistics), LD clumping is not applicable for this dataset [67]. Finally, we selected 1433 LD independent top eQTL SNPs as the MR instrumental variables.

PsychENCODE eQTL. The PsychENCODE eQTL were generated using brain tissues (the prefrontal cortex) of 1,378 human individuals [63]. The PsychENCODE eQTL summary data were downloaded from the SMR website (https://cnsgenomics.com/software/smr/re/qTLsummarydata) [68]. eQTL Summary data (corrected for 50 PEER factors were used. A total of 2,542,908 SNP-gene expression pairs were included in PsychENCODE dataset. SNPs were retained if the target genes (i.e., genes whose expression were associated with these SNPs) of these SNPs were included in the 1263 drug targets. For each gene, only SNPs with eQTL P values less than 1 x 10^{-6} were included. We performed LD clumping by using clump function in TwoSampleMR R package (https://mrcieu.github.io/TwoSampleMR/reference/clump_data.html) [67], with the use of default LD clumping parameters, i.e., the clumping r² cutoff was set to 0.001 and “EUR” was selected as LD reference panel. The LD reference panel of the European (EUR) population was obtained from the 1000 Genomes project provided by OpenGWAS API (https://gwas-api.mrcieu.ac.uk) [69, 70]. A total of 926 LD independent eQTL SNPs were finally included as instrumental variables in the MR analysis. Please refer to the original paper for further details about the PsychENCODE eQTL data [63]. For genes with two or more independent instrumental variables, we performed heterogeneity test by using the mr_heterogeneity() function implemented in the TwoSampleMR R package [67].

ROSMAP pQTL. The protein QTL (pQTL) data were from a recent study by Wingo et al. [64]. Briefly, Wingo et al. performed a pQTL analysis in the prefrontal cortex to identify genetic variants associated with protein abundance in the human brain. We downloaded the pQTL summary statistics (ROSMAP, n = 376) generated by Wingo et al. from Synapse (https://doi.org/10.7303/syn23627957). A total of 912,253 SNP-protein expression pairs were included in the ROSMAP pQTL dataset and SNPs were extracted if they showed significant associations with expression of actionable proteins (pQTL P < 0.05). LD clumping was conducted as described in above PsychENCODE eQTL dataset. We finally selected 626 pQTL SNPs for 445 drug target proteins as MR instrumental variables. Further information about ROSMAP pQTL data, please refer to the original publication [64]. Heterogeneity test was also performed as described in above PsychENCODE eQTL dataset when more than two instruments are available for a protein [67].

GWAS summary statistics used in this study

We used genome-wide summary statistics of four common psychiatric disorders [41, 45–47], including schizophrenia, BP, depression and ADHD. The GWAS summary statistics were downloaded from the PGC website (https://www.med.unc.edu/pgc/download-results/). The GWAS results were used as outcome data in MR analysis. For schizophrenia, we used GWAS results of European populations (33,640 SCZ cases and 43,456 controls) reported by Lam et al. [41]. For BP, we used the largest GWAS (41,917 BP cases and 371,549 controls) reported by Mullins et al. [46]. The depression GWAS summary statistics were from a large-scale GWAS study (170,756 cases, 329,443 controls) by Howard et al. [45]. The ADHD GWAS were performed in 20,183 ADHD cases and 35,191 controls [47].

Mendelian randomization

The TwoSampleMR R package (version 0.5.6, https://mrcieu.github.io/TwoSampleMR/) were used to perform two sample MR analysis [67]. The two-sample MR framework requires two datasets to conduct MR analysis. In this study, the cis eQTL and pQTL data were used as genetic proposed instruments (exposure), and the GWASs were used as the outcome trait data. MR tests the relationship between gene expression and diseases or traits by using genetic variants associated with gene expression (exposure) as instrumental variables and GWAS as outcomes. MR could investigate if change of gene expression has causal effects on diseases or traits. For proposed instruments with one SNP, Wald ratio was used. For proposed instruments containing more than one SNP, fixed-effects,
consistent pQTL panel was included in this study. We corrected the 11 eQTL panels used in this study, including 10 GTEx eQTL panels and PsychENCODE eQTL panels, obtaining the final Bonferroni correction threshold: \(3.96 \times 10^{-5}/11 = 3.60 \times 10^{-6}\) for eQTL MR analysis. For pQTL panel we used a relatively relaxed correction threshold: \(0.05/445 = 1.12 \times 10^{-4}, 445\) is the number of actionable drug targets that had instruments included in the pQTL data). No further correction was applied for pQTL MR analysis as only one pQTL panel was included in this study.

Consistency analysis between transcriptomic and proteomic associations
To investigate whether there is a consistency between transcriptomic and proteomic associations, we performed a correlation analysis on MR effect (odds ratio, OR) between transcriptomic and proteomic associations as described in a recently published study [71]. In brief, we select \(P = 1 \times 10^{-4}\) as the threshold for QTL instrumental variables for PsychENCODE eQTL and ROSMAP pQTL datasets. SCZ genome-wide summary statistics from European ancestry (33,640 cases and 43,456 controls) were used as outcomes. R function cor() was used to perform Pearson correlation analysis of the MR effect of PsychENCODE eQTL and ROSMAP pQTL MR analysis results.

Genome-wide Mendelian randomization by including all proteins
In addition to the actionable druggable targets, we also performed a genome-wide Mendelian randomization by including pQTL of all proteins. The selection of instrumental variables was the same as described in above PsychENCODE eQTL dataset. In total, we selected 1357 LD-independent pQTL instruments of 1295 proteins. The multiple correction level was set at \(P = 3.86 \times 10^{-5}\) (Bonferroni correction 0.05/1295).

Protein-protein interaction (PPI) analysis
We performed protein-protein interaction (PPI) analysis to investigate the PPI of the significant MR drug targets. The PPIs were retrieved from our previous study which includes 517,927 high-confidence (i.e., experimentally validated) non-overlapping PPIs [72]. Please refer to the original paper for further information about the PPI datasets. Visualization of the PPI network was performed in Cytoscape platform (https://cytoscape.org/) [73].

Expression analysis of the identified genes in different cell types of the human brain and protein expression pattern analysis
We utilized the Cortical Development Expression Viewer (CoDex) data portal to explore the expression pattern of the MR significant genes at the single cell level. The CoDex database includes expression profile (measured by RNA sequencing) of approximately 40,000 single cell from the developing human cortex. Detailed information about the CoDex database and the single cell data can be found in the original paper [74] and the CoDex website (http://scola.top.ucla.edu/shiny/webapp/).

We also performed protein expression analysis of the identified drug targets using The Human Protein Atlas (proteinatlas.org) database [75]. The Human protein atlas includes protein expression data of 44 human tissues, more details about human protein atlas is available in the original publication and the website (https://www.proteinatlas.org/about/publications) [75].

RESULTS
MR analysis identifies 12 actionable therapeutic targets for SCZ
MR analysis could make causal inference to investigate if gene or protein expression change causes disease. Thus, the significant genes or proteins identified by MR can be used as potential therapeutic targets. Using cis eQTL SNPs from GTEx as genetic instruments, we identified 8 actionable drug targets for schizophrenia (MR \(P < 3.60 \times 10^{-6}\)) (Fig. 1a). These potential actionable drug targets include HLA-DRB1, BRD2, CHRNA2, RORB, CACNA1C, MAPK3, PTK6 and CYP2D6 (Fig. 1a, Table 1). Of note, CACNA1C had the most significant MR result \((P = 3.23 \times 10^{-15}), OR [95%CI] = 0.85\) [0.81, 0.88]. HLA-DRB1 is supported by genetic instruments from three different brain regions. BRD2 and HLA-DRB1 are located in the major histocompatibility complex (MHC) region, which contains the most significant genetic association signals for SCZ [40].

We identified 3 significant associations (AKT3, PSMA4 and PTK6) when using cis eQTL SNPs from PsychENCODE as genetic instruments (Fig. 1b, Table 1). Interestingly, PTK6 was supported by both GTEx \((P = 1.53 \times 10^{-6}, OR [95%CI] = 0.90 [0.86, 0.94])\) and PsychENCODE \((P = 2.31 \times 10^{-6}, OR [95%CI] = 0.49 [0.37, 0.66])\) eQTL datasets. We also identified significant MR results for 4 proteins (HLA-DRB1, CAMKK2, P2RX7 and MAPK3), suggesting that abundance change of these 4 proteins have a causal role in SCZ (Fig. 1c, Table 1).

We observed 3 consistent MR results between SCZ and BP risk proteins. Using GTEx eQTL as genetic instruments, and 5 genes (DCLK3, SRPK2, DAGLA, PSDM3 and STK4) were identified by using PsychENCODE eQTL. We also identified significant MR results for 1 protein (PRKCB) (Fig. 2, Table S1). Five genes (CACNA1C, DAGLA, SRPK2, PSDM3 and STK4) were nominated by the BP GWAS. No overlapping genes were observed in the 3 QTL panels (Fig. 2). However, we observed overlapping MR results between SCZ and BP (Figs. 1, 2). The CACNA1C gene is the top MR hit for BP (GTEx eQTL) (Fig. 2a, \(P = 3.31 \times 10^{-13}\), OR [95%CI] = 0.89 [0.85, 0.92]) and SCZ (GTEx eQTL) (Fig. 1a). In addition, we noticed that two independent instruments (rs57968099, rs5613451) were identified for DCLK3 gene (Table S1). MR result \(P = 6.05 \times 10^{-13}\), OR [95%CI] = 0.51 [0.42, 0.61], heterogeneity test \(P = 0.79\) in our MR result.

Identification of 7 actionable therapeutic targets for depression
We identified 7 actionable targets for BP. CACNA1C was identified by using GTEx eQTL as genetic instruments, and 5 genes (DCLK3, SRPK2, DAGLA, PSDM3 and STK4) were identified by using PsychENCODE eQTL. We also identified significant MR results for 1 protein (PRKCB) (Fig. 2, Table S1). Five genes (CACNA1C, DAGLA, SRPK2, PSDM3 and STK4) were nominated by the BP GWAS. No overlapping genes were observed in the 3 QTL panels (Fig. 2). However, we observed overlapping MR results between SCZ and BP (Figs. 1, 2). The CACNA1C gene is the top MR hit for BP (GTEx eQTL) (Fig. 2a, \(P = 3.31 \times 10^{-13}\), OR [95%CI] = 0.89 [0.85, 0.92]) and SCZ (GTEx eQTL) (Fig. 1a). In addition, we noticed that two independent instruments (rs57968099, rs5613451) were identified for DCLK3 gene (Table S1). MR result \(P = 6.05 \times 10^{-13}\), OR [95%CI] = 0.51 [0.42, 0.61], heterogeneity test \(P = 0.79\) in our MR result.

Identification of 7 actionable therapeutic targets for depression
We identified a total of 7 actionable targets for depression (Fig. 3, Table S1), including 1 gene STK24 (MR \(P = 1.29 \times 10^{-6}, OR [95\% CI] = 1.05 [1.03, 1.07]\) from GTEx eQTL dataset (Fig. 3a) and 6 proteins from ROSMAP pQTL (PSMB4, SERPINC1, IMPDH2, GRIAT1, TAOK3 and P2RX7) (Fig. 3c). Of note, 3 genes (STK24, IMPDH2 and P2RX7) were nominated as risk genes in the original depression GWAS.

We observed protein-protein interactions between the significant MR proteins. For example, PSMB4 interacts with PSMA4 and PSDM3 (Fig. S2), and GRIAT1 interacts with PRKCB (Fig. S2). These results suggest the physical interactions between the nominated risk proteins.

Identification of TIE1 as a potential drug target for ADHD
Only one significant MR result (TIE1) was identified for ADHD (Fig. 4b, \(P = 2.12 \times 10^{-07}\), OR [95%CI] = 1.56 [1.32, 1.85]). Interestingly, TIE1 is
not nominated by the original ADHD GWAS. No significant MR results were identified in GTEx eQTL and ROSMAP pQTL panels. The top finding in GTEx eQTL panel (Fig. 4a, CD40) and ROSMAP pQTL (Fig. 4c, ITGA5) were marked in Fig. 4.

Expression of the identified genes in different cell types of the human brain
We explored the expression pattern of the prioritized genes using the single cell RNA sequencing data. Among genes associated with SCZ, AKT3, BRD2, CAMKK2, PSMA4 and RORB, are widely expressed in different brain cell types at relatively high level (Figs. S3–S6). RORB, MAPK3 and AKT3 are highly expressed in human brain tissues, while PSMA4, CACNA1C and PTK6 show moderate expression (Figs. S11–S14). For BP, DCLK3, PSMD3, SRPK2, and STK4 are widely expressed in different brain cell types (Figs. S7, S8). However, PRKCB is specifically expressed in excitatory deep layer 1 (Fig. S7b). SRPK2 and PSMD3 proteins are highly expressed in human brain tissues (Fig. S15). For depression, GRIA1, IMPDH2, PSMB4, STK24 and TAOK3, are widely expressed in different brain cell types (Figs. S8–S10). STK24, IMPDH2 and

Fig. 1  The Manhattan plots of MR analysis results using QTLs and SCZ GWAS summary statistics (33,640 SCZ cases and 43,456 controls). The red dashed line is the Bonferroni corrected significant level. a The MR result using GTEx brain eQTL as instruments. b The MR result using PsychENCODE eQTL as instruments. c The MR result using ROSMAP pQTL as instruments.
SCZ, which is consistent with our previous genes (as therapeutic targets) could increase the success rate of drug development substantially [48]. Thus, leveraging GWASs may provide new opportunities to develop drugs for psychiatric disorders. In this study, we conducted comprehensive MR analyses to identify potential causal genes for psychiatric disorders. By focusing on druggable genes or proteins, we prioritized 46 actionable drug targets for four common psychiatric disorders (schizophrenia, BP, depression and ADHD). Our results provide actionable promising candidates for drug repurposing for psychiatric disorders. CACNA1C had the most significant MR results among the prioritized targets for SCZ, strongly suggesting that this gene represents a promising drug target for SCZ. CACNA1C encodes the alpha-1 (Cav1.2) subunit of a voltage-dependent calcium channel, which mediates the influx of calcium ions into the cell [77]. CACNA1C regulates gene expression and synaptic plasticity by initiating downstream signaling cascades [78]. Genetic variants in CACNA1C showed robust associations with SCZ and BP [78], and mouse models also revealed psychiatric-like and mood phenotypes in Cacna1c heterozygous deletion mice [78]. These lines of convergent evidence indicate the pivotal role of CACNA1C in psychiatric disorders. Of note, dihydropyridine could inhibit CACNA1C. Thus, this gene is a promising drug target for SCZ and BP. We checked the ChEMBL database (https://www.ebi.ac.uk/chembl/) and found that DRONEDARONE for SCZ and BP. We found that Dronedarone inhibits CACNA1C. Thus, this gene is a promising drug target for SCZ and BP.

Other interesting candidate targets for SCZ include MAPK3 and PSMA4. MR analysis indicated that MAPK3 showed significant associations with SCZ in both eQTL and pQTL datasets, implying

**DISCUSSION**

Development of novel therapeutic drugs for psychiatric disorders has been proved to be extremely challenging. A major reason for this plight is the unknown pathophysiology of psychiatric disorders. In the past decade, large-scale genetic studies have identified multiple risk variants for psychiatric disorders. These GWASs have provided important biological insights into psychiatric disorders. In fact, human genetics could provide important information to inform drug development and a recent study by Nelson et al. showed that selecting genetically supported target genes (as therapeutic targets) could increase the success rate of drug development substantially [48]. Thus, leveraging GWASs may provide new opportunities to develop drugs for psychiatric disorders. In this study, we conducted comprehensive MR analyses to identify potential causal genes for psychiatric disorders. By focusing on druggable genes or proteins, we prioritized 46 actionable drug targets for four common psychiatric disorders (schizophrenia, BP, depression and ADHD). Our results provide actionable promising candidates for drug repurposing for psychiatric disorders. CACNA1C had the most significant MR results among the prioritized targets for SCZ, strongly suggesting that this gene represents a promising drug target for SCZ. CACNA1C encodes the alpha-1 (Cav1.2) subunit of a voltage-dependent calcium channel, which mediates the influx of calcium ions into the cell [77]. CACNA1C regulates gene expression and synaptic plasticity by initiating downstream signaling cascades [78]. Genetic variants in CACNA1C showed robust associations with SCZ and BP [78], and mouse models also revealed psychiatric-like and mood phenotypes in Cacna1c heterozygous deletion mice [78]. These lines of convergent evidence indicate the pivotal role of CACNA1C in psychiatric disorders. Of note, dihydropyridine could inhibit CACNA1C. Thus, this gene is a promising drug target for SCZ and BP. We checked the ChEMBL database (https://www.ebi.ac.uk/chembl/) and found that DRO- NEDARONE (CHEMBL184412), which was approved by Food and Drug Administration (FDA), could target voltage-gated L-type calcium channel proteins (including CACNA1C, CACNA1D, CACNA1S and CACNA1F), suggesting the therapeutic potential of DRONEDARONE for SCZ and BP.

Other interesting candidate targets for SCZ include MAPK3 and PSMA4. MR analysis indicated that MAPK3 showed significant associations with SCZ in both eQTL and pQTL datasets, implying

**Table 1.** The Mendelian Randomization results of brain QTL datasets (GTEx eQTL, PsychENCODE eQTL and ROSMAP pQTL) and schizophrenia GWAS.

| Gene          | Instruments | Method        | Instruments dataset | MR P value | Beta | OR [95% CI] |
|---------------|-------------|---------------|---------------------|------------|------|-------------|
| HLA-DRB1      | rs296961    | Wald ratio    | GTEx (Brain Cortex) | 1.04 × 10⁻⁹ | 0.059 | 1.06 [1.04, 1.08] |
| BRD2          | rs209474    | Wald ratio    | GTEx (Brain Cerebellum) | 3.08 × 10⁻⁹ | −0.17 | 0.84 [0.80,0.89] |
| HLA-DRB1      | rs9270692   | Wald ratio    | GTEx (Brain Cerebellar Hemisphere) | 6.47 × 10⁻⁸ | 0.055 | 1.06 [1.04, 1.08] |
| HLA-DRB1      | rs9281938   | Wald ratio    | GTEx (Brain Nucleus accumbens basal ganglia) | 8.41 × 10⁻⁸ | 0.046 | 1.05 [1.03, 1.06] |
| CHRNA2        | rs11783093  | Wald ratio    | GTEx (Brain Cerebellum) | 1.78 × 10⁻⁸ | −0.085 | 0.92 [0.89, 0.95] |
| ROR8          | rs11144082  | Wald ratio    | GTEx (Brain Cerebellum) | 1.78 × 10⁻⁶ | 0.16 | 1.17 [1.10, 1.25] |
| CACNA1C       | rs7297582   | Wald ratio    | GTEx (Brain Cerebellum) | 3.23 × 10⁻¹⁵ | −0.17 | 0.85 [0.81, 0.88] |
| MAPK3         | rs28529403  | Wald ratio    | GTEx (Brain Frontal Cortex BA9) | 1.55 × 10⁻⁶ | 0.13 | 1.14 [1.08, 1.20] |
| CYP2D6        | rs2142694   | Wald ratio    | GTEx (Brain Frontal Cortex BA9) | 2.92 × 10⁻⁷ | −0.066 | 0.94 [0.91, 0.96] |
| CYP2D6        | rs2267448   | Wald ratio    | GTEx (Brain Cerebellar Hemisphere) | 4.52 × 10⁻⁷ | −0.053 | 0.95 [0.93, 0.97] |
| PTK6          | rs139707650 | Wald ratio    | GTEx (Brain Cerebellar Hemisphere) | 1.53 × 10⁻⁶ | −0.10 | 0.90 [0.86, 0.94] |
| CYP2D6        | rs2743451   | Wald ratio    | GTEx (Brain Frontal Cortex BA9) | 4.97 × 10⁻⁷ | −0.066 | 0.94 [0.91, 0.96] |
| CYP2D6        | rs2284087   | Wald ratio    | GTEx (Brain Hippocampus) | 3.16 × 10⁻⁶ | −0.064 | 0.94 [0.91, 0.96] |
| AKT3          | rs3008660   | Wald ratio    | PsychENCODE         | 7.82 × 10⁻⁷ | −1.29 | 0.28 [0.17, 0.46] |
| PSMA4         | rs28498264  | Wald ratio    | PsychENCODE         | 1.09 × 10⁻¹⁰ | 1.70 | 5.48 [3.27, 9.19] |
| PTK6          | rs2150808   | Wald ratio    | PsychENCODE         | 2.31 × 10⁻⁶ | −0.71 | 0.49 [0.37, 0.66] |
| HLA-DRB1      | rs502771    | Wald ratio    | ROSMAP              | 1.15 × 10⁻⁸ | 0.50 | 1.65 [1.39, 1.96] |
| CAMKK2        | rs3794207;  | Inverse variance | ROSMAP             | 9.68 × 10⁻⁶ | −1.15 | 0.32 [0.19, 0.53] |
| P2RX7         | rs3751143   | Wald ratio    | ROSMAP              | 5.00 × 10⁻⁵ | −0.15 | 0.86 [0.80, 0.93] |
| MAPK3         | rs11865086  | Wald ratio    | ROSMAP              | 2.38 × 10⁻⁵ | 1.93 | 6.91 [2.82, 16.93] |
the causal effects of expression change of these two genes in SCZ. Many studies, including genetic study [40], transcriptome and proteome profiling [79], integrative analysis [80], network-based prioritization [81] and functional genomics study [82], have showed the pivotal role of MAPK3 in SCZ. For example, MAPK3 has been reported to be dysregulated in schizophrenia cases compared with healthy controls ($P = 0.0001$) [79]. The potential role of PSMA4 in SCZ was also supported by large-scale GWAS [40] and a recent prioritization study [81]. These results highlight the pivotal role of MAPK3 and PSMA4 in SCZ. Thus, these two genes may be served as promising therapeutic targets for SCZ treatment. MAPK3 is a potential target of SORAFENIB (CHEMBL1336), and PSMA4 (20S proteasome subunit alpha-3) is a potential target of CARFILZOMIB (CHEMBL451887, targeting 26S proteasome). Our MR analysis suggested that SORAFENIB and CARFILZOMIB may be repositioned for schizophrenia treatment. However, further clinical trials are needed.

For depression, interesting protein candidates include PSMB4, GRIA1 and TAOK3. Interestingly, a previous study also has revealed the potential role of PSMB4 in depression [83]. Glutamate

---

**Fig. 2** The Manhattan plot of MR analysis using QTLs and BP GWAS summary statistics (41,917 BP cases and 371,549 controls). The red dashed line is the Bonferroni corrected significant level. a The MR result using GTEx brain eQTL as genetic instruments. b The MR result using PsychENCODE eQTL as genetic instruments. c The MR result using ROSMAP pQTL as genetic instruments.
ionotropic receptor AMPA type subunit 1 (GRIA1) has a critical role in glutamate-mediated neurotransmission and synaptic plasticity. In fact, the rapid antidepressant ketamine is an inhibitor of N-methyl D-aspartate (NMDA) receptors, indicating the crucial role of glutamate signaling in depression. TAOK3 is a serine/threonine protein kinase that regulates the p38/MAPK14 stress-activated MAPK cascade and the MAPK8/JNK cascade [84, 85]. Interestingly, previous studies have reported the crucial role of MAPK signaling in depression [86–89]. These lines of evidence support that TAOK3 and MAPK signaling pathway may be a promising target for depression treatment.

Only TIE1 gene is significant in our MR analysis for ADHD. TIE1 encodes a transmembrane tyrosine-protein kinase. TIE1 has been reported as one of the significant genes in a Transcriptome-wide association study (TWAS) of ADHD [90], suggesting that the expression level change of TIE1 gene may have a role in ADHD etiology. These evidence supported that TIE1 may be served as a promising therapeutic drug target for ADHD.

Fig. 3  The Manhattan plot of MR analysis result using QTLs and depression GWAS summary statistics (170,756 cases, 329,443 controls). The red dashed line is the Bonferroni corrected significant level. a The MR result using GTEx brain eQTL as instruments. b The MR result using PsychENCODE eQTL as instruments. c The MR result using ROSMAP pQTL as instruments.
The candidate genes identified by MR varied across the 4 psychiatry disorders (e.g., 12 for SCZ, and only 7 for depression and 1 for ADHD, respectively). Following reasons may lead to this result: First, the sample size included in the original genome-wide association studies (GWASs) of different psychiatric disorders were different. For example, the SCZ GWAS included 33,640 cases and 43,456 controls. However, the sample size included in the ADHD GWAS was smaller (20,183 ADHD patients and 35,191 controls). The larger sample size, the higher power to detect the associations between common variations and diseases. Second, the heritability of these psychiatric disorders are different [91–94]. The heritability of depression (about 30–40%) is much smaller than other psychiatric disorders [91–94]. Accordingly, the number of identified candidate genes for depression is less than SCZ. In addition, our significant MR analysis findings were not supported by both eQTL and pQTL MR analysis. The potential reasons may due to the weak correlation between mRNA expression level and protein level as previously [95] reported. Besides, the number of instruments and sample size of pQTL panel is smaller than eQTL panels, leading to less proteins were included in MR.

Fig. 4 The Manhattan plot of MR analysis result using QTLs and ADHD GWAS summary statistics (20,183 cases, 35,191 controls). The red dashed line is the Bonferroni corrected significant level. a The MR result using GTEx brain eQTL as genetic instruments. b The MR result using PsychENCODE eQTL as genetic instruments. c The MR result using ROSMAP pQTL as genetic instruments.
It should be noted that many genes identified in this study have been reported in previous studies [45, 76, 90, 96–102]. However, the key purpose of our study is to prioritize the actionable novel drug targets for psychiatric disorders (which is different from previous studies as the main goal of these studies is to identify risk genes). We thus believe that our findings provide critical drug-repurposing opportunities for psychiatric disorders.

In summary, we identified actionable new drugs targets for psychiatric disorders. As these proteins are targets of approved drugs or drugs in clinical phase of development, our findings prioritize actionable novel drug targets for development of new therapeutics and provide critical drug-repursposing opportunities for psychiatric disorders.

REFERENCES

1. GBD. 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789–858.

2. Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiatry. 2016;3:171–8.

3. Steel Z, Maman C, Iranpour C, Chey T, Jackson JW, Patel V, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol. 2014;43:476–93.

4. Trautmann S, Rehm J, Wittchen HU. The economic costs of mental disorders: Do we societies react appropriately to the burden of mental disorders? EMBO Rep. 2016;17:1245–9.

5. COVID-19 Mental Disorders Collaborators*. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021; https://doi.org/10.1016/S0140-6736(21)02143-7.

6. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17:1206–27.

7. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10:79–104.

8. Patel KR, Cheriaux J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P t. 2014;39:638–65.

9. Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 2012;379:1045–55.

10. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2013;381:1357–66.

11. Buckley PF. Update on the treatment and management of schizophrenia and bipolar disorder. CNS Spectr. 2008;13:1–10.

12. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2013;13:318–78.

13. Carlson A, Lindqvist M. Effect of chlorpromazine or Haloperidol on Formation of 3-Methoxytyramine and Nor-metanephrine in Mouse Brain. Acta Pharm Toxicol (Copenh). 1963;20:140–4.

14. van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther. 1966;160:492–4.

15. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47:27–38.

16. Taylor C, Fricker AD, Devi LA, Gomes I. Mechanisms of action of anti-depressants: from neurotransmitter systems to signaling pathways. Cell Sig 2005;17:549–57.

17. Brignat B. Pathophysiology of depression and mechanisms of treatment. Dialogues Clin Neurosci. 2002;4:7–20.

18. Otte C, Gold SM, Pennix BW, Panizzi CM, Etkin A, Fava M, et al. Major depressive disorder. Nat Rev Dis Prim. 2016;2:16065.

19. Uçok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry. 2008;7:58–62.

20. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81:617–22.

21. Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17:341–56.

22. Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, et al. Adverse reactions to antipsychotics. Br J Psychiatry. 2009;195:202–10.

23. Wannock JK, Kneesch JW. Adverse cutaneous reactions to antipsychotics. Am J Psychiatry, 1988;145:425–30.

24. Schmidt LG, Grohmann R, Müller-Oerlinghausen B, Ochsenfahrt H, Schönförer PS. Adverse drug reactions to first- and second-generation antipsychotics: an overview. Cleve Clin J Med. 2006;73:351–3.

25. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019;394;939–51.

26. Suzuki T, Remington G, Mulsant BH, Uchida H, Raji TK, Graff-Guerrero A, et al. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 2012;197:1–6.

27. Correll CU, Howes OD. Treatment-Resistant Schizophrenia: Definition, Predictors, and Therapy Options. J Clin Psychiatry. 2021;1;22:06914411.

28. Siskind D, Orr S, Sinha S, Yu Q, Brijball B, Warren N, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. The British Journal of Psychiatry. 2021; https://doi.org/10.1192/bjp.2021.61.

29. Nucifora FC Jr, Woznica E, Lee BJ, Cassella N, Sawada A. Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. Neurol Biol Dis. 2019;131:104257.

30. Al-Harbì KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369–88.

31. Howes OD, Thase ME, Pillinger T Treatment resistance in psychiatry: state of the art and new directions. Mol Psychiatry. 2021; https://doi.org/10.1038/s41380-021-01200-3.

32. Little JT, Reynolds CF 3rd, Deva MA, Frank E, Begley AE, Miller MD, et al. How common is resistance to treatment in recurrent, nonpsychotic geriatric depression? Am J Psychiatry. 1998;155:1035–8.

33. Agid Y, Buzsáki G, Diamond DM, Frackowiak R, Giedd J, Girault JA, et al. How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discn. 2007;6:189–201.

34. Editorials. Psychiatric drug discovery on the couch. Nat Rev Drug Discn. 2007; 6:171.

35. Zampori GW. Targeting voltage-gated calcium channels in neurological and psychiatric diseases. Nat Rev Drug Discn. 2016;15:19–34.

36. Kesselheim AS, Hwang TJ, Franklin JM. Two decades of new drug development for central nervous system disorders. Nat Rev Drug Disc. 2015;14:815–6.

37. Reay WR, Cairns MZ. Advancing the use of genome-wide association studies for drug repurposing. Nat Rev Genet. 2021;21:658–71.

38. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511:421–7.

39. Lam M, Chen CY, Li Z, Martin AR, Bryois J, Ma X, et al. Comparative genetic architectures of schizophrenia in East Asian and European populations. Nat Genet. 2019;51:1670–8.

40. Shi Y, Li Z, Xu Q, Wang T, Li T, Shen J, et al. Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nat Genet. 2011;43:1224–7.

41. Yue WH, Wang HF, Sun SD, Fang PL, Liu ZH, Zhang HX, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018;50:668–81.

42. Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22:343–52.

43. Mullins N, Forister AJ, O’Connell KS, Coombes B, Coleman JR, Qiao Z, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat Genet. 2021; 53:817–29.

44. Delemont D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the first genome-wide significant risk loci for attention deficit/ hyperactivity disorder. Nat Genet. 2019;51:63–75.
55. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation

59. Larsson SC, Traylor M, Malik R, Dichgans M, Burgess S, Markus HS. Modifi

54. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal

53. Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW, et al. Integrative

62. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx)

61. Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, et al.

6 4 . W i n go A P , L i u Y , G e r a s i m o v E S , G o c k l e y J , L o g s d o n B A , D u o n g D M , et a l.

65. Liu A, Manuel AM, Dai Y, Zhao Z. Prioritization of risk genes in multiple sclerosis

69. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global

73. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a

87. Fang K, Xu JX, Chen XX, Gao XR, Huang LL, Du AQ, et al. Differential serum

86. Cheng SW, Li JX, Chien YC, Chang JP, Shityakov S, Huang SY, et al. Genetic

89. Wang JQ, Mao L. The ERK Pathway: Molecular Mechanisms and Treatment of

84. Kapfhamer D, King I, Zou ME, Lim JP, Hebelein U, Wolf FW. JNK pathway

81. Ma C, Gu C, Huo Y, Li X, Luo XJ. The integrated landscape of causal genes and

83. Föcking M, Lopez LM, English JA, Dicker P, Wolff A, Brindley E, et al. Proteomic

88. Humo M, Ayazgok B, Becker LJ, Waltisperger E, Rantamaki T, Yalcin I. Ketamine

85. Li Z, Oh H, Cung M, Marquez SJ, Sun J, Hammad H, et al. TAOK3 is a MAP3K

80. Gusev A, Mancuso N, Won H, Kousi M, Finucane HK, Reshef Y, et al.

82. Kibinge NK, Relton CL, Gaunt TR, Richardson TG. Characterizing the Causal

89. Sullivan PF, Neale MC, Kendler KL. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157:1552–67.

90. Aglio L, Lewis CM, Pain O. Delineating the Genetic Component of Gene

91. Zhu Z, Zhong F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene tar-

92. Bhargava RS, Shigeoka S, Chiosis GL, et al. A small molecule that induces rapid and sustained antidepressant-like effects in chronic pain induced depression: Role of MAPK signaling pathway. Prog Neuropsychopharmacol Biol Psychiatry. 2020;100:109898.

93. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003;60:1187–92.

94. Auerbach RS, Cattaneo E. The ERK Pathway: Molecular Mechanisms and Treat-

95. Ahlers JA, Lindemann EP, Cullinan PA, et al. The effect of ketamine on prefrontal cortical glutamate receptor function in depression. Biol Psychiatry. 2015;77:150–54.

96. Auerbach RS, Cattaneo E. The ERK Pathway: Molecular Mechanisms and Treat-

97. Zhang Q, Zhong F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene tar-

98. Bhargava RS, Shigeoka S, Chiosis GL, et al. A small molecule that induces rapid and sustained antidepressant-like effects in chronic pain induced depression: Role of MAPK signaling pathway. Prog Neuropsychopharmacol Biol Psychiatry. 2020;100:109898.

99. Auerbach RS, Cattaneo E. The ERK Pathway: Molecular Mechanisms and Treat-

100. Auerbach RS, Cattaneo E. The ERK Pathway: Molecular Mechanisms and Treat-

Neuropsychopharmacology (2023) 48:270 – 280

J. Liu et al. 279
ACKNOWLEDGEMENTS
We thank Miss. Qian Li for her technical assistance.

AUTHOR CONTRIBUTIONS
XJL conceived, designed and supervised the whole study. JWL performed the analyses. XJL, JWL, QYC, ML, ZJZ and TL wrote the manuscript. All authors provided critical comments and approved the final manuscript.

FUNDING
This study was equally supported by the Distinguished Young Scientists grant of the Yunnan Province (202001AV070006) and the Key Research Project of Yunnan Province (202101AS070055 to XJL). Also was supported by the National Nature Science Foundation of China (U2102205 and 31970561 to XJL), the CAS “Light of West China” Program (to JWL), the Yunnan Fundamental Research Projects (202001AT070099 to JWL), and the National Natural Science Key Foundation of China (No. 81830040 and 82130042 to ZJZ).

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41386-022-01456-5.

Correspondence and requests for materials should be addressed to Xiong-Jian Luo.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.